Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing-Reference-Cited by-同舟云学术

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing

Published:2010-03 Issue:5 Volume:18 Page:1844-1853
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Brasca Maria Gabriella,Albanese Clara,Alzani Rachele,Amici Raffaella,Avanzi Nilla,Ballinari Dario,Bischoff James,Borghi Daniela,Casale Elena,Croci Valter,Fiorentini Francesco,Isacchi Antonella,Mercurio Ciro,Nesi Marcella,Orsini Paolo,Pastori Wilma,Pesenti Enrico,Pevarello Paolo,Roussel Patrick,Varasi Mario,Volpi Daniele,Vulpetti Anna,Ciomei Marina

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference16 articles.

1. Cell cycle, CDKs and cancer: a changing paradigm

2. To cycle or not to cycle: a critical decision in cancer

3. N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

4. Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023);Pharmaceutical Fronts;2024-09-03

2. Inhibitors identify an auxiliary role for mTOR signalling in necroptosis execution downstream of MLKL activation;Biochemical Journal;2024-08-27

3. Three candidate anticancer drugs were repositioned by integrative analysis of the transcriptomes of species with different regenerative abilities after injury;Computational Biology and Chemistry;2023-10

4. Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases;Cancers;2023-07-25

5. Pan-Cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer;Frontiers in Immunology;2023-03-16